05:54 AM EDT, 05/14/2024 (MT Newswires) -- Hutchmed ( HCM ) said Tuesday it started a phase 2/3 trial of its drug candidate surufatinib in combination with nab-paclitaxel, gemcitabine and Jiangsu Hengrui's camrelizumab as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma in China.

The company said the trial's first patient received the first dose on May 8 and after an initial safety run-in stage, the phase 2/3 stage of the trial may enroll 500 additional patients.

The trial's primary endpoint is overall survival and other endpoints include objective response rate and progression-free survival, among others.

Price: 21.98, Change: +0.20, Percent Change: +0.92